I25 Stock Overview
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
iRhythm Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$98.50 |
| 52 Week High | US$121.00 |
| 52 Week Low | US$65.50 |
| Beta | 1.31 |
| 1 Month Change | -3.43% |
| 3 Month Change | -7.94% |
| 1 Year Change | -10.45% |
| 3 Year Change | 50.38% |
| 5 Year Change | 60.24% |
| Change since IPO | 319.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| I25 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.3% | -0.5% | -0.3% |
| 1Y | -10.5% | -10.1% | 2.8% |
Return vs Industry: I25 matched the German Medical Equipment industry which returned -11.2% over the past year.
Return vs Market: I25 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| I25 volatility | |
|---|---|
| I25 Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I25 has not had significant price volatility in the past 3 months.
Volatility Over Time: I25's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,000 | Quentin Blackford | www.irhythmtech.com |
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period.
iRhythm Technologies, Inc. Fundamentals Summary
| I25 fundamental statistics | |
|---|---|
| Market cap | €2.97b |
| Earnings (TTM) | -€120.68m |
| Revenue (TTM) | €476.53m |
6.5x
P/S Ratio-25.6x
P/E RatioIs I25 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I25 income statement (TTM) | |
|---|---|
| Revenue | US$513.17m |
| Cost of Revenue | US$169.53m |
| Gross Profit | US$343.64m |
| Other Expenses | US$473.61m |
| Earnings | -US$129.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.18 |
| Gross Margin | 66.96% |
| Net Profit Margin | -25.33% |
| Debt/Equity Ratio | 713.3% |
How did I25 perform over the long term?
See historical performance and comparison